Opinion|Videos|September 3, 2024
Real-World Treatment of BPH: Outcomes and Patient Education
Fact checked by: Dean Elterman, MD, MSc
Dean Elterman, MD, discusses real-world outcomes of minimally invasive surgical therapies for benign prostate dysplasia, including improvements in quality of life, symptom relief, comparisons with clinical study results, and general patient feedback, while also sharing tips for building rapport and educating patients on their treatment options.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- Please speak to the real-world outcomes of minimally invasive surgical therapy treatments for benign prostate dysplasia you observe in your practice:
- How do outcomes improve patients’ quality of life and other symptoms?
- How do real-world results compare with what various clinical studies have shown?
- Please share general feedback highlights you receive from patients.
- We have already discussed the importance of patient preference in choosing the best treatment. Do you have any tips for how to build rapport and educate patients on their options?
Advertisement
Related to this article
Juan J. Andino, MD, MBA, discusses surgical decision-making in prolonged ischemic priapism and how ischemia duration affects erectile dysfunction risk and treatment timing.
Jack R. Andrews, MD, discusses BED-PSMA-411 findings comparing PSMA-PET detection rates and urinary excretion in prostate cancer biochemical recurrence.
Sandip Prasad, MD, MPhil, discusses ENVISION trial findings on mitomycin for intravesical solution and patient selection in clinical practice.
OpenFlo incorporates a design that modifies key mechanical features of conventional Foley catheters.
Study design discussions can help patients weigh personalized marketing claims, according to Jean Cunningham, PharmD, BCPS.
VIR-5500 is a PSMA-targeted PRO-XTEN dual-masked T-cell engager entering phase 3 development for prostate cancer.
Marie-Pier St-Laurent, MD, FRCSC, explains how NeoBLAST combines imaging, TURBT, and ctDNA to identify candidates for bladder-sparing surveillance.
Bladder symptoms during IVF often reflect hormonal and pelvic floor changes, not infection, according to Aleece Fosnight, MSPAS, PA-C.
Advertisement
Advertisement
Trending on Urology Times
1
Study compares PSMA-PET radiopharmaceuticals in prostate cancer recurrence
2
Variation in PSMA PET Adoption for Prostate Cancer Care
3
Prostate Cancer Case Review: Biochemical Recurrence and a Rib Lesion
4
ENVISION data inform the use of chemoablation in recurrent LG-IR-NMIBC
5